COMP <GO>
NRC vs ABSI // EV/EBITDA & P/E VALUATION
NRC Health (NASDAQ) VS. Absci Corporation (NASDAQ) • 15-METRIC TALLY: NRC 5
— ABSI 1
■ METRIC PARITY
LAST: $23.49 (+0.09%) • MKT CAP: $519.6M
valuation
18.6x
LAST: $12.10 (+1.85%) • MKT CAP: $2.08B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRC VS. ABSI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NRC | ABSI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | -35.00% | +56.00 | NRC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 18.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.03% | -4.53% | +7.56 | NRC | /fcf-yield <GO> |
| Operating Margin | 16.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 8.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -4.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.11% | 0.00% | +2.11 | NRC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.82 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | NRC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 57.7 | +8.95 | NRC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.6M | $2.08B | -$1.56B | ABSI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NRC REV | ABSI REV | NRC GROSS % | ABSI GROSS % | NRC FCF | ABSI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $137.4M | $0 | — | — | $15.7M | -$94.0M |
| FY 2024 | $143.1M | $4.5M | — | — | $19.2M | -$72.8M |
| FY 2023 | $148.6M | $5.7M | — | — | $38.1M | -$64.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRC // BETA —
ABSI // BETA —